

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for categories:

Investment Rational

Gina life, a **Masschallenge winner**, is leading a paradigm shift in early detection in women's diseases, by developing a new approach: **vaginal secretions analysis**. The company is in clinical trials with leading clinical centers, initiating clinical trials in the USA and has recently participated in the **MayoClinic** highly competitive accelerator. The company recently completed its seed round and approaching A-round.

○ **Business Strategy**

The first product, a test for early detection of ovarian cancer will be used to screen women at risk, women with pathologies in the ovaries and the general population. The test is an at home, do-it-yourself, guided by an app. Additional indications such as endometrial cancer, endometriosis and more will be launched to strengthen the platform.

○ **Core Technology**

Gina Life is developing a platform which enables vaginal secretions analysis. The company's technology enables extraction of important clinical data from vaginal secretions by combining high clinical and biological expertise empowered by machine learning and artificial intelligence. Gina Life's mission is to disrupt women's health space by making early detection easy and affordable anytime anywhere.

○ **Product Profile/Pipeline**

- Gina Life is in the midst of a clinical trial, with more than 1000 participants, towards proof of concept. Women's health market is a growing market, each indication in the pipeline has the potential of capturing \$B size market.

Gina Life participated in the competitive MayoClinic accelerator, and is working with leading clinical and academic institution towards proof-of-concept.

○ **What's Next?**

Gina Life will initiate US clinical trial in Q2 2023 towards proof of concept which will enable the product launch. The company is in its growth stage with major stakeholders joining as investors and collaborators.